Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseRadiationC3Hf/Sed//Kam and C57BL/6 gnotobioticMale and femalen = n = 8 per group for dose modification and screening; mean s…Subcutaneous, dissolved in 15 microlitres DMSO and suspended in 1 mL of 1 per cent Cremophor EL in water, given in 0.2 mL volumes; compound 5 was also effective by oral gavage5 mg/kg was optimal and generally superior to 75, 40, 10, 2…Starting 24 hours after whole body irradiation; less effective at 48 hours and…
Model: Whole body irradiation using an AEC Gamma Cell 40 caesium-137 irradiator at about 60 cGy/min; LD70/30 estimates 7.725 Gy for C3H and 8.509 Gy for C57BL/6. Partial body irradiation with 300 kV X-rays under Cerrobend shielding: 18 Gy local abdominal irradiation, 14 and 18 Gy local thoracic irradiation, 4 Gy thoracic in the tumour model
All six in vitro active compounds improved 30-day survival after LD70/30 whole body irradiation when given subcutaneously at 5 mg/kg daily for 5 days starting 24 hours after exposure, raising mean survival time from 17 to 18.5 days and shifting LD50/30 from 7.5 Gy to 8.0 Gy for compound 5. Lead com…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
